Claims for Patent: 8,685,934

Summary for Patent: 8,685,934

Title:	Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
Abstract:	The invention provides methods for treating a patient having type 2 diabetes who has failed on previous regimens of one or more oral and/or injectable anti-diabetic agents, which include the step of administering a therapeutically effective amount of an SGLT2 inhibitor alone or in combination with another anti-diabetic agent and/or other therapeutic agent to such patient. A pharmaceutical composition containing dapagliflozin or dapagliflozin-S-propylene glycol solvate and one or more diabetic agents and/or other therapeutic agents for use in the methods of the invention is also provided.
Inventor(s):	Strumph; Paul (Pennington, NJ), Moran; Stephanie (Princeton, NJ), List; James (Princeton, NJ)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:	13/321,103
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,685,934
Patent Claims:	1. A method for treating extreme insulin resistance in a mammalian patient, wherein the patient has previously been treated with .gtoreq.50 units of insulin per day and at least one or more of metformin, pioglitazone, or rosiglitazone, and wherein the previous treatment provided inadequate glycemic control (HbA.sub.1c<7%) the method comprising: administering to said patient in need of treatment a therapeutically effective amount of an SGLT2 inhibitor of formula: ##STR00030## or a prodrug ester thereof or a propylene glycol solvate thereof. 2. The method as defined in claim 1 wherein the patient is treated with the SGLT2 inhibitor in combination with one or more of insulin, metformin, glyburide, glipizide, pioglitazone, rosiglitazone, saxagliptin, vildagliptin, sitagliptin or exenatide. 3. The method as defined in claim 1 wherein the SGLT2 inhibitor is administered in an amount within the range from about 0.5 to about 350 mg/day. 4. The method as defined in claim 2 wherein the patient is treated with an SGLT2 inhibitor in combination with a) insulin; or b) insulin and metformin; or c) insulin and a thiazolidinedione; or d) insulin and metformin and a thiazolidinedione. 5. The method according to claim 1, wherein the SGLT2 inhibitor is: ##STR00031## 6. The method as defined in claim 4 wherein the SGLT2 inhibitor is (a) dapagliflozin or dapagliflozin-PGS at a dose from about 0.5 to about 200 mg/day is administered in combination with insulin at a dose as prescribed by a physician or as described in the PDR; or (b) dapagliflozin or dapagliflozin-PGS at a dose from about 0.5 to about 200 mg/day is administered in combination with insulin at a dose as prescribed by a physician or as described in the PDR, and metformin at a dose from about 500 to about 2000 mg/day; or (c) dapagliflozin or dapagliflozin-PGS at a dose from about 0.5 to about 200 mg/day is administered in a combination with insulin at a dose as prescribed by a physician or as described in the PDR, pioglitazone at a dose from about 0.5 to about 75 mg/day, or rosiglitazone at a dose from about 0.5 to about 25 mg/day; or (d) dapagliflozin or dapagliflozin-PGS at a dose from about 0.5 to about 200 mg/day is administered in combination with insulin at a dose as prescribed by a physician or as described in the PDR, metformin at a dose from about 500 to about 2000 mg/day, and pioglitazone at a dose from about 0.5 to about 75 mg/day or rosiglitazone at a dose from about 0.5 to about 25 mg/day. 7. The method according to claim 1, wherein the SGLT2 inhibitor is administered at a dose from about 0.5 to about 350 mg, in combination with: a) metformin; or b) pioglitazone or rosiglitazone; or c) insulin; or d) metformin and insulin; or e) pioglitazone or rosiglitazone and metformin; or f) pioglitazone or rosiglitazone and insulin; or g) metformin, pioglitazone or rosiglitazone and insulin. 8. A method for providing glycemic control (HbA.sub.1c<7.0%) to a patient, wherein glycemic control is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone, the method comprising administering to said patient a therapeutically effective amount of an SGLT2 inhibitor of formula: ##STR00032## or a prodrug ester thereof or a propylene glycol solvate thereof. 9. A method according to claim 8, wherein the SGLT2 inhibitor is: ##STR00033## 10. The method as defined in claim 8 wherein the SGLT2 inhibitor is (a) dapagliflozin or dapagliflozin-PGS at a dose from about 0.5 to about 200 mg/day is administered in combination with insulin at a dose as prescribed by a physician or as described in the Physicians' Desk Reference (PDR); or (b) dapagliflozin or dapagliflozin-PGS at a dose from about 0.5 to about 200 mg/day is administered in combination with insulin at a dose as prescribed by a physician or as described in the PDR, and metformin at a dose from about 500 to about 2000 mg/day; or (c) dapagliflozin or dapagliflozin-PGS at a dose from about 0.5 to about 200 mg/day is administered in a combination with insulin at a dose as prescribed by a physician or as described in the PDR, pioglitazone at a dose from about 0.5 to about 75 mg/day, or rosiglitazone at a dose from about 0.5 to about 25 mg/day; or (d) dapagliflozin or dapagliflozin-PGS at a dose from about 0.5 to about 200 mg/day is administered in combination with insulin at a dose as prescribed by a physician or as described in the PDR, metformin at a dose from about 500 to about 2000 mg/day, and pioglitazone at a dose from about 0.5 to about 75 mg/day or rosiglitazone at a dose from about 0.5 to about 25 mg/day. 11. A method according to claim 8, wherein the patient further has extreme insulin resistance. 12. A method according to claim 11, wherein .gtoreq.50 units of insulin per day and at least one or more of metformin, pioglitazone, or rosiglitazone was ineffective to provide adequate glycemic control (HbA.sub.1c<7%). 13. A method according to claim 8, wherein the SGLT2 inhibitor is administered in an amount within the range from about 0.5 to about 350 mg/day.